New Oral GLP-1 Beats Oral Semaglutide for A1c, Weight Loss
Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D) inadequately controlled by metformin, a phase 3 randomized controlled trial showed. “The primary objective of non-inferiority was met, and both orforglipron doses showed superiority to both semaglutide doses,” lead author […]
New Oral GLP-1 Beats Oral Semaglutide for A1c, Weight Loss Read More »
